Journal
SIGNAL TRANSDUCTION AND TARGETED THERAPY
Volume 5, Issue 1, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41392-020-00352-y
Keywords
-
Categories
Funding
- Chinese National Natural Science Funds [82041009, 31925013, 31671457, 91753139, 31871405]
- Ministry of Science and Technology of China [2016YFA0502500]
- Jiangsu Provincial Distinguished Young Scholars award [BK20180043]
- Zhejiang Natural Science Fund [LD19C070001]
- Key Project of University Natural Science Foundation of Jiangsu Province [19KJA550003]
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Zhejiang University Joint Pingduoduo Virus Infectious Disease Prevention and Control funds
Ask authors/readers for more resources
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that is highly pathogenic and has caused the recent worldwide pandemic officially named coronavirus disease (COVID-19). Currently, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Vaccines, such as inactivated vaccines, nucleic acid-based vaccines, and vector vaccines, have already entered clinical trials. In this review, we provide an overview of the experimental and clinical data obtained from recent SARS-CoV-2 vaccines trials, and highlight certain potential safety issues that require consideration when developing vaccines. Furthermore, we summarize several strategies utilized in the development of vaccines against other infectious viruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), with the aim of aiding in the design of effective therapeutic approaches against SARS-CoV-2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
